Preliminary cruise report ATLANTIS II - cruise 8 : International Indian Ocean Expedition, July 5, 1963 - December 20, 1963

Originally issued as Reference No. 64-11, series later renamed WHOI-.ATLANTIS II was delivered to the Woods Hole Oceanographic Institution on January 31, 1963. After some short cruises she left Woods Hole on July 5 to participate in the International Indian Ocean Expedition, her first major effort of long duration since her delivery. Eight was a strict test of the capabilities , endurance, Cruise facilities and comfort for which she was designed. The investigations in the Indian Ocean were per haps unique among other cruises of the Exped~t ion in that full coverage of the Arabian Sea was obtained during the Southwest Monsoon in August and September. Further coverage to the south was obtained in October and November where southeast winds were predominant. Inclusion of the Red Sea as part of the Expedition, the total number of hydrographic stations completed during this portion of the cruise was 193, consisting of observations more or less at standard depths to the bottom. These observations, together with various meteorological measurements and chemical analyses are being processed and evaluated, Geophysical observations such as bathymetry and magnetometer results are also being processed along with the navigational positions from the VLF Navigation System.Sponsored by Grant NSF-GP 821 from the National Science Foundatio

Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta-analysis.

This is the final version. Available from Springer via the DOI in this record. Data Availability: The datasets analyzed during the current study are available from the corresponding author on reasonable request.INTRODUCTION: Randomized controlled trials (RCTs) comparing triple therapies (inhaled corticosteroid [ICS], long-acting β2-agonist [LABA], and long-acting muscarinic antagonist [LAMA]) for the treatment of chronic obstructive pulmonary disease (COPD) are limited. This network meta-analysis (NMA) investigated the comparative efficacy of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus any triple (ICS/LABA/LAMA) combinations and dual therapies in patients with COPD. METHODS: This NMA was conducted on the basis of a systematic literature review (SLR), which identified RCTs in adults aged at least 40 years with COPD. The RCTs compared different ICS/LABA/LAMA combinations or an ICS/LABA/LAMA combination with any dual therapy (ICS/LABA or LAMA/LABA). Outcomes of interest included forced expiratory volume in 1 s (FEV1), annualized rate of combined moderate and severe exacerbations, St George's Respiratory Questionnaire (SGRQ) total score and SGRQ responders, transition dyspnea index focal score, and rescue medication use (RMU). Analyses were conducted at 24 weeks (primary endpoint), and 12 and 52 weeks (if feasible). RESULTS: The NMA was informed by five trials reporting FEV1 at 24 weeks. FF/UMEC/VI was statistically significantly more effective at increasing trough FEV1 (based on change from baseline) than all triple comparators in the network apart from UMEC + FF/VI. The NMA was informed by 17 trials reporting moderate or severe exacerbation endpoints. FF/UMEC/VI demonstrated statistically significant improvements in annualized rate of combined moderate or severe exacerbations versus single-inhaler budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR). At 24 weeks, the NMA was informed by five trials. FF/UMEC/VI showed statistically significant improvements in annualized rate of combined moderate or severe exacerbations versus UMEC + FF/VI and BUD/GLY/FOR. FF/UMEC/VI also demonstrated improvements in mean SGRQ score versus other triple therapy comparators at 24 weeks, and a significant reduction in RMU compared with BUD/GLY/FOR (160/18/9.6). CONCLUSION: The findings of this NMA suggest favorable efficacy with single-inhaler triple therapy comprising FF/UMEC/VI. Further analysis is required as additional evidence becomes available.GlaxoSmithKlei

CHRONIC REPRODUCTIVE FAILURES AT A BALD EAGLE (HALIAEETUS-LEUCOCEPHALUS) NESTING TERRITORY IN NORTHERN CALIFORNIA

Volume: 29Start Page: 35End Page: 3

INVESTIGATIONS OF THE DECLINE OF SWAINSON\u27S HAWK POPULATIONS IN CALIFORNIA USA

Volume: 23Start Page: 63End Page: 7